iRhythm TechnologiesIRTC
About: iRhythm Technologies Inc is a commercial-stage digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining wearable biosensing technology with cloud-based data analytics and machine-learning capabilities. The company's portfolio includes ambulatory cardiac monitoring services on a platform, called the Zio service, which combines an easy-to-wear and unobtrusive biosensor that can be worn for several days with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company derived its revenue from the United States.
Employees: 2,000
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
64% more call options, than puts
Call options by funds: $66.8M | Put options by funds: $40.8M
53% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 32
28% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 67
6% more funds holding
Funds holding: 225 [Q2] → 238 (+13) [Q3]
5.58% less ownership
Funds ownership: 118.35% [Q2] → 112.76% (-5.58%) [Q3]
34% less capital invested
Capital invested by funds: $3.96B [Q2] → $2.61B (-$1.35B) [Q3]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
Needham David Saxon 36% 1-year accuracy 23 / 64 met price target | 0%downside $112 | Buy Maintained | 13 Jan 2025 |
Oppenheimer Suraj Kalia 67% 1-year accuracy 16 / 24 met price target | 7%upside $120 | Outperform Maintained | 8 Jan 2025 |
Truist Securities Richard Newitter 74% 1-year accuracy 31 / 42 met price target | 1%downside $111 | Buy Maintained | 18 Dec 2024 |
Canaccord Genuity William Plovanic 71% 1-year accuracy 35 / 49 met price target | 36%upside $152 | Buy Maintained | 9 Dec 2024 |
Wells Fargo Nathan Treybeck 25% 1-year accuracy 1 / 4 met price target | 23%downside $86 | Equal-Weight Reinstated | 3 Dec 2024 |
Financial journalist opinion
Based on 16 articles about IRTC published over the past 30 days









